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Summary
Background—Some evidence suggests that an inadequate vitamin D level may increase the risk
atherosclerotic cardiovascular disease. Whether low vitamin D has a role in venous
thromboembolism (VTE), i.e., venous thrombosis and pulmonary embolism, is largely
unexplored.
Objectives—We tested prospectively in the Atherosclerosis Risk in Communities (ARIC) cohort
whether the serum concentration of 25-hydroxyvitamin D (25(OH)D) is inversely associated with
VTE incidence and whether it partly explains the African American excess of VTE in ARIC.
Patients and Methods—We measured 25(OH)D using mass spectroscopy in stored samples of
12,752 ARIC study participants and followed them over a median of 19.7 years (1990-92 through
2011) for incidence of VTE (n = 537).
Results—The seasonally-adjusted 25(OH)D concentration was not associated with VTE
incidence. In a model adjusted for age, race, sex, hormone replacement therapy, and body mass
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index, the hazard ratios of VTE across 25(OH)D quintiles 5 (high) to 1 (low) were: 1 (Ref.), 0.84
(0.65, 1.08), 0.88 (0.68, 1.13), 1.04 (0.78, 1.38), and 0.90 (0.64, 1.27). The lowest 25(OH)D
quintile comprised 59% African Americans, whereas the highest quintile comprised 7% African
Americans. Yet, lower 25(OH)D concentrations explained little of the 63% greater VTE risk of
African Americans over whites in this cohort.
Conclusions—Low 25(OH)D was not a risk factor for VTE in this prospective study. Yet, the
totality of literature (three studies) suggests that low 25(OH)D might modestly increase VTE risk
in whites, but this needs further confirmation.
Keywords
Prospective studies; pulmonary embolism; risk factors; venous thrombosis; vitamin D
There is considerable interest in the role of vitamin D in human health. The best marker of
vitamin D status is serum 25-hydroxyvitamin D [25(OH)D] [1]. An area that needs
clarification is whether a low level of 25(OH)D may predispose to venous
thromboembolism (VTE), as it may do for atherothrombotic diseases. Lindqvist et al
suggested this possibility by showing in a cohort of Swedish women that sunbathers (with,
presumably, extra sun-induced vitamin D had a 30% reduced VTE risk, and that population
VTE risk was 50% lower in summer than winter (when vitamin D levels decrease) [2]. A
large prospective study from Copenhagen reported an inverse association of seasonally-
adjusted plasma 25(OH)D with VTE, with a relative risk of 1.28 (95% CI = 1.06, 1.53) for
the lowest versus highest tertile of 25(OH)D [3]. However, the Tromsø Study found no
association of serum 25(OH)D with VTE, but was underpowered for low versus high
25(OH)D quartiles (relative risk 1.32, 95% CI = 0.78, 2.22) [4]. Administration of calcitriol,
the active hormone form of vitamin D, was shown to reduce VTE occurrence in chronic
kidney disease [5] and cancer patients [6]. Vitamin D receptor −/− mice, who display
vitamin D deficiency, have increased thrombogenic activity [7].
25(OH)D levels are seemingly deficient in 38% of black women, 18% of black men, 5% of
white women, and 1% of white men, and they are optimal in only 2%, 4%, 29%, and 26%,
respectively [8]. Grant speculated that a link between low vitamin D and VTE might explain
an African American excess of VTE, compared with whites [9]. However, along with lower
mean levels of 25(OH)D, recent evidence suggests that African Americans also have lower
levels of vitamin D-binding protein and hence mean levels of bioavailable vitamin D similar
to those in whites [10].
We tested prospectively in the Atherosclerosis Risk in Communities (ARIC) cohort whether
25(OH)D is inversely associated with VTE incidence and partly explains the African
American excess of VTE in our sample [11].
Methods
Study population
The ARIC Study [12] and its methods for identification and classification of VTE have been
described in detail elsewhere [11, 13]. In brief, in 1987-89, 15,792 men and women aged 45
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to 64 years from four U.S. communities (Forsyth County, NC; Jackson, MS; suburban
Minneapolis, MN; Washington County, MD; ranging in latitude from 32.3° N to 45.0° N)
enrolled in the ARIC Study. The cohort underwent four subsequent examinations and annual
telephone contact. The present analysis used ARIC visit 2 (1990-92) as its start point for
VTE follow-up through 2011. The institutional review committees at each study center
approved the methods, and staff obtained informed participant consent.
Measurement of 25(OH)D and VTE risk factors
All risk factors were measured at the 1990-92 ARIC visit 2, except for the sports physical
activity score, factor VIII, and activated partial thromboplastin time (APTT), which were
available from the previous 1987-89 ARIC visit [14, 15]. Participants were asked to fast for
12 hours before their morning visit 2 appointments, and serum and plasma samples were
obtained and stored at −80 °C. Soon after the visit, central laboratories measured serum
creatinine by the Jaffe method and glucose by a hexokinase assay. In 2012-13, a number of
analytes, including vitamin D, were measured on a previously unthawed visit 2 serum
aliquot. 25(OH)D [sum of 25(OH)D2 and 25(OH)D3] was measured using liquid
chromatography-tandem high-sensitivity mass spectrometry (Waters Alliance e2795,
Milford, Massachusetts). Using duplicate samples collected at visit 2 and stored, we
calculated the 25(OH)D coefficient of variation (CV) as 10.9%. This CV encompasses
variability related to both sample processing and laboratory methods. Calcium and
phosphorous were measured using colorimetric methods on a Roche Modular P Chemistry
Analyzer with reagents from Roche Diagnostics Corporation (Indianapolis, IN). The CVs
were 2.4% for calcium and 3% for phosphorous. Intact parathyroid hormone (PTH) was
measured on a Roche Elecsys 2010 Analyzer using a sandwich immunoassay method (CV,
9.7%). High sensitivity C-reactive protein (CRP) was assayed using a latex-particle
enhanced immunoturbidimetric assay kit (Roche Diagnostics) and read on the Roche
Modular P Chemistry analyzer (CV, 7%). Cystatin C was measured using Gentian Cystatin
C reagent on the Roche Modular P Chemistry analyzer (CV, 3%).
Cigarette smoking, education level attained, and history of cancer were obtained by self-
report. Sports physical activity was assessed by the Baecke questionnaire [16] and yielded a
score from 1 (low) to 5 (high). Current hormone replacement therapy was queried in women
and medication bottles were inspected to verify ARIC visit 2 use. Diabetes was defined as a
fasting blood glucose of 126 mg/dl or higher, non-fasting blood glucose of 200 mg/dl or
higher, a self-reported physician diagnosis of diabetes, or use of antidiabetic medication in
the past 2 weeks. Glomerular filtration rate (eGFR) was estimated from cystatin C and
creatinine using the Chronic Kidney Disease Collaboration algorithm [17]. Height to the
nearest centimeter and weight to the nearest pound were measured with participants in scrub
suits and without shoes. Body mass index was calculated as weight (kg)/height (m)2.
VTE occurrence
ARIC participants are contacted annually by phone and asked about all hospitalizations in
the previous year. Hospital records with discharge diagnoses for possible VTE events [12]
were obtained from baseline through 2011. To validate the VTE events, two physicians
(ARF, MC) reviewed the records using standardized criteria [12]. A diagnosis of deep vein
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thrombosis (DVT) or pulmonary embolism (PE) required positive imaging tests. We
restricted DVTs for this analysis to those in the lower extremity or vena cava. Cases were
classified by the reviewers as unprovoked (no obvious cause) or provoked (associated with
recent hospitalization cancer, major trauma, surgery, marked immobility).
Statistical analysis
Of the 14,348 participants at ARIC visit 2, we excluded those who did not have 25(OH)D
measurements (n = 1,198), had a prior VTE (n = 264), were taking anticoagulants (n = 93),
were not white or African American (n = 38), or had no follow-up (n = 3). This left 12,752
participants (n = 9,618 whites and 3,134 African Americans) for the present analyses
relating 25(OH)D to incident VTE. Time at risk was computed from the date of visit 2 to the
earliest of the following: date of hospital discharge with incident VTE, date of death, date of
last follow-up contact, or end of follow-up (December 31, 2011).
Our main hypothesis was that 25(OH)D levels would be associated inversely with VTE
incidence. Since serum 25(OH)D levels vary greatly by sun exposure, which is seasonal, we
accounted for seasonal variation by computing the residuals from race-specific linear
regression models with 25(OH)D as the dependent variable and month of blood draw as the
independent variable. The grand mean was added to the 25(OH)D residuals to create a new
variable, “25(OH)D adjusted for month of blood draw,” which was used as the main
exposure variable. 25(OH)D was modeled either as a continuous variable or categorized into
percentiles of the overall distribution: 75-100 (reference), 50-74, 25-49, 10-24, and 0-9%.
Cox proportional hazards models were used to calculate hazard ratios (HR) and 95%
confidence intervals of incident VTE. We verified the proportional hazards assumption of
the Cox models by inspection of ln(-ln) survival curves for 25(OH)D categories. We
selected possible confounding variables for regression models based on our previous
prospective findings [13-15]. We subsequently examined and ruled out a few additional
possible confounders suggested by reviewers of this report (i.e., smoking, physical activity,
education level, and cancer history). Final Model 1 adjusted for age (continuous), sex, and
race (African American, white), and also verified that there was no significant sex or race by
25(OH)D interaction. Model 2 adjusted for age, race, sex/hormone replacement therapy
(male, women using hormone replacement therapy (HRT), women not using HRT) and body
mass index (continuous). Adding smoking status, sports activity score, education, and cancer
history to Model 2 had no impact, and so these covariates were dropped. Model 3 added
diabetes status (yes or no) and CRP (continuous). Model 4 added eGFR, PTH, calcium, and
phosphorous (all continuous). Model 5 added Factor VIII and aPTT (both continuous) from
ARIC visit 1. Whether 25(OH)D explains the African American excess of VTE was tested
by comparing the race coefficient with and without 25(OH)D in Model 2. Ultimately, we did
not show Models 3 in Table 1 and 5 in any tables, because results for Models 2 through 5
were similar.
Results
At baseline the mean (SD) serum 25(OH)D concentration was 24.3 (8.5) ng/mL (18.9
mg/mL in African Americans and 26.1 mg/mL in whites), and the median was 23.8 ng/mL.
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As expected, lower 25(OH)D percentiles had a greater proportion of African Americans
(Table 1), and most other characteristics varied by percentile.
During a median of 19.7 years of follow-up, 537 incident VTEs were identified (n = 349 in
whites and 188 in African Americans; 336 provoked and 201 unprovoked). The
Supplemental Table shows crude incidence rates of VTE according to levels of participant
characteristics.
Adjusted for age, sex, and race (Model 1), there was no apparent association between
25(OH)D and VTE whether categorized on the basis of percentiles or analyzed per SD
increment of 25(OH)D (Table 2). In the percentile model, the association was similar for
men and women (i.e., sex by 25(OH)D interaction term p-value = 0.49) but appeared non-
significantly stronger in whites than African Americans (race by 25(OH)D interaction term
p-value = 0.10). When stratified by race (not shown in Table 2), the Model 1 hazard ratios
(95% CI) across the five descending percentile groupings were 1 (ref), 0.96 (0.73, 1.26),
0.87 (0.64, 1.16), 1.32 (0.94, 1.86), and 1.44 (0.91, 2.26) in whites, whereas in African
Americans the hazard ratios were 1 (ref), 0.63 (0.33, 1.18), 0.97 (0.56, 1.66), 0.94 (0.54,
1.64), and 0.82 (0.46, 1.47).
In the more fully adjusted models (Table 2), there was no evidence in the overall ARIC
sample of an association of 25(OH)D with VTE. This was also true when we looked
separately at provoked and unprovoked VTE (data not shown). There was also no evidence
for association between 25(OH)D and VTE (n = 152 VTEs) when limited to the first 10
years of follow-up (and thus closer to the vitamin D measurement).
Since the previous two studies of 25(OH)D included only whites, we excluded African
Americans calculated VTE hazard ratios for whites in ARIC (Table 3). When participants in
the lowest quartile of 25(H)D were pooled and compared to the highest quartile, the Model 1
hazard ratio (1.36; 95% CI = 1.00, 1.83) was slightly elevated (p=0.05). However, there was
no evidence of a dose-response, and adjustment for body mass index and hormone
replacement therapy eliminated the association for quartile four versus one (Table 3, Model
2).
The hazard ratio of VTE for African Americans relative to whites was 1.63 (95% CI = 1.36,
1.97), adjusted for age, sex/HRT, and body mass index (BMI). When 25(OH)D percentiles
were added to this model, the hazard ratio for race changed only to 1.62 (95% CI = 1.33,
1.98), suggesting that racial differences in 25(OH)D concentration explain little of the
greater VTE risk of African Americans over whites in this cohort.
Discussion
This prospective population-based cohort study found no significant association between
serum 25(OH)D levels and incidence of VTE over two decades of follow-up. Not
surprisingly, therefore, racial differences in 25(OH)D did not explain why African
Americans had a 63% higher VTE risk than did whites in this cohort.
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Our results showing no association are consistent with the Tromsø Study, with n = 201
VTEs [4]. It is less consistent with the Copenhagen Study (n = 950 VTEs) which reported a
weak inverse association between 25(OH)D and VTE [3]. All three studies appear to be of
high quality, with 25(OH)D measured on blood samples stored more than a decade. The
Copenhagen Study had the greatest statistical power among these three epidemiologic
studies, but our study also had a large number of VTEs (n = 537). The two European studies
included only whites, and our findings for whites alone hinted at a nonsignificant association
between 25(OH)D and VTE, but none at all in African Americans. Interestingly, another
study suggested low 25(OH)D is a stronger risk factor for arterial cardiovascular events in
whites than African Americans [18]. In all three VTE studies, the 25(OH)D association (in
whites) tended to be for low versus high 25(OH)D and not apparent across the entire
25(OH)D range. Meta-analyzing the hazard ratios of 1.28, 1.32, and 1.14 for the highest
versus lowest 25(OH)D categories in the Copenhagen, Tromsø, and ARIC (whites) studies
yields a pooled hazard ratio estimate of 1.25 (95% CI = 1.07, 1.45) with no evidence of
between-study heterogeneity. Thus, the totality of evidence suggests that low 25(OH)D is
associated with a modestly increased VTE risk.
Given that 25(OH)D was not associated overall with VTE incidence in ARIC, it was not
surprising that lower levels of 25(OH)D did not explain the higher VTE risk of African
Americans than whites. If African Americans and whites have similar levels of bioavailable
vitamin D, as has been suggested [10], then that would also argue against differences in
vitamin D levels contributing importantly to racial differences in VTE.
Some methodologic aspects of this study warrant consideration. Firstly, 25(OH)D in ARIC
was measured on serum samples stored at −80 °C for two decades. Evidence exists that
25(OH)D is stable over at least four years [19] and is unaffected by multiple freeze-thaw
cycles [20, 21]. Any sample deterioration, if uniform across the 25(OH)D distribution,
should not have biased our results. Secondly, we had only a single measurement of
25(OH)D, and over the long follow-up participants 25(OH)D levels may have fluctuated.
The Copenhagen Study reported a two decade 25(OH)D reliability coefficient of r = 0.45
[3], similar to the long-term reliability of other nutritional biomarkers. Thus,
misclassification of 25(OH)D is substantial and would tend to weaken observed associations
with VTE. Seasonal variation in 25(OH)D is another potential source of misclassification,
but we and the two other cohort studies controlled for seasonal variation. Thirdly, we
captured hospitalized VTEs only, but several pilot studies in ARIC have suggested that the
vast majority of initial VTEs are hospitalized.
Conclusions
We did not find low 25(OH)D to be a risk factor for VTE in this prospective study. Yet, the
totality of literature (three studies) suggests that low 25(OH)D might modestly increase VTE
risk in whites. Possible future research might include more observational studies, including
nonwhites; basic studies of 25(OH)D and thrombus generation; and examining VTE as an
outcome in ongoing vitamin D supplementation trials.
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